<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581670</url>
  </required_header>
  <id_info>
    <org_study_id>1437</org_study_id>
    <nct_id>NCT02581670</nct_id>
  </id_info>
  <brief_title>Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer</brief_title>
  <official_title>Prospective Non-randomized Phase II Study on Stereotactic Body Radiation Therapy for Medically Inoperable Lung and Liver Oligometastases From Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators designed a phase II study to evaluate safety and efficacy of lung and liver
      stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for
      surgery, using VMAT RapidArc approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators designed a prospective phase II study to evaluate safety and efficacy of lung
      and liver stereotactic radiation therapy (SRT) scheduled for oligometastatic breast cancer
      patients unsuitable for surgery with age major than 18 years old and with adequate
      performance status (ECOG), using VMAT RapidArc approach. The potential advantage of this
      technique is the ability to deliver a more selective irradiation to tumour's target while
      reducing doses to normal tissue, optimizing the therapeutic window.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity in oligometastatic breast cancer patients monitoring using CTCAE v.4</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local control of disease after SBRT according to EORTC questionnaire</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival using Kaplan-Meyer statistical curves</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival using Kaplan-Meyer statistical curves</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at the end of the treatment with questionnaire EORTC QLQ C30</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis to Liver</condition>
  <condition>Metastasis to Lung</condition>
  <arm_group>
    <arm_group_label>Oligometastatic breast cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiation therapy (SRT)</intervention_name>
    <description>Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach</description>
    <arm_group_label>Oligometastatic breast cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt;18 years with ECOG 0-2

          -  Diagnosis of Breast Cancer

          -  DFI (Disease-free interval) &gt; 1 year

          -  No extrapulmonary and/or extrahepatic disease or other metastatic sites stable or
             responding after chemotherapy

          -  No life threatening conditions

          -  Lung and liver lesions &lt; 5 (with maximum diameter &lt; 5 cm)

          -  Chemotherapy completed at least 3 weeks before treatment

          -  Chemotherapy started at least 2 weeks after treatment allowed

          -  Systemic therapies other than chemotherapy allowed (i.e hormonal therapies and/or
             immunotherapy)

          -  Written informed consent

        Exclusion Criteria:

          -  ECOG &gt; 2

          -  Pregnant women

          -  Patients with inability to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fiorenza De Rose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiziana Comito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fiorenza De Rose, MD</last_name>
    <phone>+390282247307</phone>
    <email>fiorenza.de_rose@cancercenter.humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorenza De Rose, MD</last_name>
      <phone>+390282247307</phone>
      <email>fiorenza.de_rose@cancercenter.humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Tiziana Comito, MD</last_name>
      <phone>+390282247244</phone>
      <email>tiziana.comito@cancercenter.humanitas.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>oligometastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

